Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Change in Receivables (2016 - 2025)

Immucell's Change in Receivables history spans 16 years, with the latest figure at $864243.0 for Q4 2025.

  • For Q4 2025, Change in Receivables fell 40.94% year-over-year to $864243.0; the TTM value through Dec 2025 reached -$352124.0, down 122.21%, while the annual FY2025 figure was -$352124.0, 122.21% down from the prior year.
  • Change in Receivables reached $864243.0 in Q4 2025 per ICCC's latest filing, up from $175943.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $1.5 million in Q4 2024 to a low of -$1.2 million in Q2 2022.
  • Average Change in Receivables over 5 years is $81110.4, with a median of $280050.0 recorded in 2021.
  • Peak YoY movement for Change in Receivables: plummeted 264.1% in 2022, then skyrocketed 896.63% in 2023.
  • A 5-year view of Change in Receivables shows it stood at $271974.0 in 2021, then tumbled by 79.13% to $56770.0 in 2022, then soared by 465.08% to $320798.0 in 2023, then soared by 356.12% to $1.5 million in 2024, then plummeted by 40.94% to $864243.0 in 2025.
  • Per Business Quant, the three most recent readings for ICCC's Change in Receivables are $864243.0 (Q4 2025), $175943.0 (Q3 2025), and -$967602.0 (Q2 2025).